https://doi.org/10.4081/btvb.2023.70
Gene transfer in hemophilia B: a big step forward
Submitted: 17 March 2023
Accepted: 21 April 2023
Published: 17 May 2023
Accepted: 21 April 2023
Abstract Views: 820
PDF: 237
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Not available
Pipe SW, Leebeek FWG, Recht M, et al. gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med 2023;388:706-18.
DOI: https://doi.org/10.1056/NEJMoa2211644
Miesbach W, Meijer K, Coppens M, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood 2018;131:1022-31.
DOI: https://doi.org/10.1182/blood-2017-09-804419
Batty P, Lillicrap D. Hemophilia gene therapy: approaching the first licensed product. Hemasphere 2021;5:e540.
DOI: https://doi.org/10.1097/HS9.0000000000000540
Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009;361:1671-5.
DOI: https://doi.org/10.1056/NEJMoa0904377
George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high- specific-activity factor IX variant. N Engl J Med 2017;377:2215-27.
DOI: https://doi.org/10.1056/NEJMoa1708538
Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med 2022;386:1013-25.
DOI: https://doi.org/10.1056/NEJMoa2113708
Nathwani AC, Tuddenham EG, Rangarajan S et al. Adenovirus-associated virus vector- mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-65.
DOI: https://doi.org/10.1056/NEJMoa1108046
Nathwani AC, Reiss U, Tuddenham E, et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing "empty viral particles" on safety and efficacy of gene transfer. Blood 2018;132:491.
DOI: https://doi.org/10.1182/blood-2018-99-118334
von Drygalski A, Gomez E, Giermasz A, et al. Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. Blood Adv 2022 [Online ahead of print].
DOI: https://doi.org/10.1182/bloodadvances.2022008886
Mahlangu J, Kaczmarek R, von Drygalski A et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med 2023;388:694-705.
DOI: https://doi.org/10.1056/NEJMoa2211075
Fahs SA, Hille MT, Shi Q, et al. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 2014;123:3706-13.
DOI: https://doi.org/10.1182/blood-2014-02-555151
Schmidt M, Foster G, Coppens M, et al. Liver safety case report from the phase 3 HOPE- B gene therapy trial in adults with hemophilia B. Res Pract Thromb Haemost 2021;5.
Mancuso ME, Lubetsky A, Pan-Petesch B, et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost 2020;18:1065-74.
DOI: https://doi.org/10.1111/jth.14778
CSL Behring. Prescribing Information - HEMGENIX 2022. Available from: https://www.fda.gov/media/163467/download. [Accessed on January 2023].
CSL Behring. HEMGENIX - Summary of Product Characteristics 2023. Available from: https://www.ema.europa.eu/en/documents/product-
information/hemgenix-epar-product-information_en.pdf [Accessed on March 2023].
Vokinger KN, Avorn J, Kesselheim AS. Sources of innovation in gene therapies- Approaches to achieving affordable prices. N Engl J Med 2023;388:292-5.
DOI: https://doi.org/10.1056/NEJMp2211729
European Association for Haemophilia and Allied Disorders. EAHAD-EHC joint statement on: promoting hub-and-spoke model for the treatment of haemophilia and rare bleeding disorders using gene therapies. Available online: http://eahad.org/wp-content/uploads/2020/05/Hub-and-Spoke.pdf [Accessed on May 2022].
Miesbach W, Chowdary P, Coppens M, et al. Delivery of AAV-based gene therapy through haemophilia centres: a need for re-evaluation of infrastructure and comprehensive care: joint publication of EAHAD and EHC. Haemophilia 2021;27:967-73.
DOI: https://doi.org/10.1111/hae.14420
How to Cite
Castaman, G. (2023). Gene transfer in hemophilia B: a big step forward. Bleeding, Thrombosis and Vascular Biology, 2(2). https://doi.org/10.4081/btvb.2023.70
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Most read articles by the same author(s)
- Giovanni Di Minno, Gaia Spadarella, Ilenia Lorenza Calcaterra, Giancarlo Castaman, Paolo Simioni, Raimondo De Cristofaro, Cristina Santoro, Flora Peyvandi, Matteo Di Minno, The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Lisa Pieri, Silvia Linari, Francesca Salvianti, Monica Attanasio, Giancarlo Castaman, Impaired platelet function in Hermansky-Pudlak syndrome associated with novel mutations in HPS3, HPS6 and HPS8 genes , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
Similar Articles
- Armando Tripodi, Remembering the XXVI SISET Congress and the 50th anniversary of its foundation, 2020 , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 1 (2025)
You may also start an advanced similarity search for this article.
